{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T22:43:12Z","timestamp":1775083392426,"version":"3.50.1"},"reference-count":0,"publisher":"Codon Publications","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergol Immunopathol"],"abstract":"<jats:p>Background:\u00a0Oral immunotherapy (OIT) is a promising approach to cow\u2019s milk and egg allergies, but reactions are frequent and some patients cannot be desensitized.\nObjective: To evaluate long-term OIT outcomes with omalizumab (OMZ) in paediatric patients with severe egg and\/or milk allergies.\nMethods:\u00a0This retrospective real-life study analysed findings in children with Immunoglobulin E-mediated allergy to cow\u2019s milk and\/or hen eggs refractory to conventional OIT, who underwent OIT with OMZ in our department between 1 January 2010 and 31 December 2015.\nResults:\u00a0In all, 41 patients were included (median age: 7 years; interquartile range [IQR]: 5.5\u20139.5); 26\/41 (63.4%) underwent OIT for milk, 8\/41 (19.5%) for egg and 7\/41 (17.1%) for both. The median time between initiation of OMZ and OIT was 27 weeks (IQR: 22\u201333). Forty (97.56%) patients reached the maintenance phase (200 mL of cow\u2019s milk and 30 mL of raw egg or 1 cooked egg) in a median time of 27 weeks (IQR: 18\u201337). The median total time with OMZ was 117 weeks (IQR: 88\u2013144). During the OMZ period, 2.44% (1\/41) of patients presented anaphylaxis. After discontinuation of OMZ, 29.3% (12\/41) presented anaphylaxis, 50% of them had a poor adherence to daily ingestion. One patient (2.44%) was diagnosed with eosinophilic esophagitis after 2 years of discontinuation of OMZ. Currently, after a median time of 9 years (IQR: 7\u201310) since the initiation of OMZ, 75.6% (31\/41) are desensitized (27\/31 without OMZ).\nConclusions:\u00a0Omalizumab allows desensitisation of children with severe allergies to cow\u2019s milk and\/or egg without developing severe reactions while receiving this treatment. However, discontinuation of OMZ leads to severe allergic reactions, and hence must be monitored carefully.<\/jats:p>","DOI":"10.15586\/aei.v50i3.537","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T15:33:04Z","timestamp":1651505584000},"page":"1-7","source":"Crossref","is-referenced-by-count":13,"title":["Long-term outcome of omalizumab-assisted desensitisation to cow\u2019s milk and eggs in patients refractory to conventional oral immunotherapy: real-life study"],"prefix":"10.15586","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5245-9847","authenticated-orcid":false,"given":"Roser","family":"Ayats-Vidal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Riera-Rubi\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Valdesoiro-Navarrete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Larramona-Carrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Asensio-De la Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Bosque-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6228","published-online":{"date-parts":[[2022,5,1]]},"container-title":["Allergologia et Immunopathologia"],"original-title":[],"link":[{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/download\/537\/813","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/download\/537\/815","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/download\/537\/814","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/download\/537\/813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T15:34:22Z","timestamp":1651764862000},"score":1,"resource":{"primary":{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/view\/537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.15586\/aei.v50i3.537","relation":{},"ISSN":["0301-0546"],"issn-type":[{"value":"0301-0546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,1]]}}}